1 Implementation of Florida s PDMP Rebecca Poston Program Manager
3 Disclaimer I have no relevant financial relationships or commercial interest in the content presented in this program.
4 Learning Objectives: Provide overview of Florida's Prescription Drug Monitoring Program regulations Discuss data reporting requirements Demonstrate practitioner/pharmacist registration Demonstrate Pharmacist/Practitioner Query for Patient Advisory Report Discuss performance measures and outcomes
6 Frequency of Occurrence of Drugs in Decedents January December 2010
7 Background: The purpose of the PDMP is to provide the information collected in the database to health care practitioners to guide their decisions in prescribing and dispensing these highly-abused prescription drugs.
8 Definitions: Section (1), F.S.: A dispenser means a pharmacy, a dispensing pharmacist, or a dispensing health care practitioner. A health care practitioner means any practitioner who is subject to licensure or regulation by the department under chapters 458, 459, 461, 462, 464, 465, or 466, F.S.
9 Definitions (cont.): Section (1), F.S.: Administer means the direct application of a controlled substance, whether by injection, inhalation, ingestion, or any other means, to the body of a person or animal.
10 Reporting Requirements: Beginning September 1, 2011, ALL dispensers of scheduled controlled substance prescriptions in schedules II, III, & IV began to report weekly The PDMP program requested that dispensers report retroactive data, from December 1, 2010 to August 31, 2011.
11 Reporting Requirements (cont.): The following information must be reported for each controlled substance dispensed to a patient: Patient Info: Prescriber Info: Demographics Demographics Date of Birth NPI number Gender DEA Number License Number
12 Reporting Requirements (cont.): Dispensing Info: Dispenser s DEA number Rx Number Date written, date filled Refill number (if applicable) NDC Quantity/Strength Dispensed Payment Type
13 Exemptions: When administering a controlled substance directly to a patient if the amount is adequate to treat the patient during that particular treatment session When administering a controlled substance dispensed to a patient receiving care in a Hospital Nursing home Ambulatory Surgical Center Hospice Intermediate care facility for the developmentally disabled
14 Exemptions (cont.): When a controlled substance is administered or dispensed in the health care system of the Department of Corrections When administering a controlled substance directly to the patient during treatment or in the emergency room of a hospital
15 Exemptions (cont.): When a controlled substance administered or dispensed to a patient under the age of 16 years old When dispensing of a one-time 72 hour emergency resupply of a controlled substance to a patient
16 Zero Reports: If a dispenser usually dispenses controlled substances in Florida but has no dispensing transactions to report for the preceding seven (7) day period, the dispenser must report this information to E-FORCSE by filing a zero report.
17 Waivers & Exemptions: Exemption from Reporting if a dispenser is registered as a dispensing practitioner in the state of Florida, but does not dispense controlled substances. Waiver from Electronic Reporting - if a dispenser is unable to report to the FL RxSentry database electronically.
18 Penalty for Non-Compliance: A health care practitioner who willfully and knowingly fails to report the dispensing of a controlled substance as required by section , F.S., commits a first degree misdemeanor.
19 Dispenser s Implementation Guide: Reporting requirements Submission methods Creating an upload account Creating a data file Reporting data Errors & Definitions
20 Accessing the Database: Section (7)(b), F.S.: A pharmacy, prescriber, or dispenser shall have access to information in the prescription drug monitoring program s database which relates to a patient of that pharmacy, prescriber, or dispenser for the purpose of reviewing the patient s controlled substance prescription history.
21 Patient Advisory Reports (PARs): Section (1)(a): information provided by the department in writing, or as determined by the department, to a prescriber, dispenser, pharmacy, or patient concerning the dispensing of controlled substances. Provided for informational purposes only and impose no obligations of any nature or any legal duty on a prescriber, dispenser, pharmacy, or patient. Not subject to discovery or introduction into evidence in any civil or administrative action.
22 Patient Advisory Reports (PARs): Section (2)(a), F.S.: Requires DOH to provide prescription information to a patient s health care practitioner and pharmacist who inform the department that they wish the PAR provided to them. The system shall be designed to provide information regarding dispensed prescriptions of controlled substances and shall not infringe upon the legitimate prescribing or dispensing of a controlled substance by a prescriber or dispenser acting in good faith and in the course of professional practice.
24 Practitioner/Pharmacist Site:
25 Training Guide for Practitioners & Pharmacists: Requesting an Account Creating query requests Viewing query request status Generating reports Viewing patient reports
26 Practitioner/Pharmacist Site:
27 Logging on to FL RxSentry (cont.): User Name: newacct Password: welcome
28 Requesting Access to Database Step 2:
29 Logging on to FL RxSentry :
30 Logging on to FL RxSentry (cont.):
31 Practitioner/Pharmacist Query:
34 Practitioner/Pharmacist Query:
35 View Query Status: Approved/Queued the query has been approved and is processing. Approved/Done the query has been approved, processed, and is available for viewing.
36 View Patient Advisory Report: Open open the PAR for viewing and printing (if desired) Save save the PAR to a specific location for viewing and printing (if desired) at a later time. Cancel
38 Performance Measures Outcome: Reduction of the rate of inappropriate use of prescription drugs through department education and safety efforts. Measure: The number of licensed prescribers, dispensers, and individuals authorized to conduct investigations that were trained in the use of the state s PDM system.
39 Number of PDMP Registered Users License Type Number of Registered Users Pharmacists 4,453 Medical Doctors 3,575 Osteopathic Physicians 653 Podiatric Physicians 43 Physician Assistants 415 Advanced Registered Nurse Practitioners 469 Dentists 318 TOTAL 9,926
40 Number of Users Trained on Use of PDMP How many licensed PRESCRIBERS were trained formally (in a classroom setting) in the use of the PDM system? 265 How many licensed PRESCRIBERS were trained informally (e.g., via the Internet, mass mailings, and so on) in the use of the PDM system? 80,376 How many licensed DISPENSERS were trained formally (in a classroom setting) in the use of the PDM system? 1,785 How many licensed DISPENSERS were trained informally (e.g., via the Internet, mass mailings, and so on) in the use of the PDM system? 30,625
41 Performance Measures Measure: The number of coroner reports that indicate controlled substance prescription drug use as the primary or contributing cause of death. Measure: The number of emergency room admissions that identify accidental controlled substance overdose as the reasons for admission.
42 Performance Measures Outcome: Reduction of the quantity of pharmaceutical controlled substances obtained by individuals attempting to engage in fraud and deceit. Measure: Increase in reports generated.
43 Number of PDMP Queries by Registered User Month Number of Queries October ,486 November ,561 December ,588 January ,552 TOTAL 505,157
44 Performance Measures Outcome: Increased coordination among partners participating in the prescription drug monitoring program. Measure: The number of licensed prescribers and distributors trained formally in coordination and data sharing.
45 Performance Measures Outcome: Involvement of stakeholders in achieving improved patient health care and safety and reduction of prescription drug abuse and prescription drug diversion. Measure: Percentage of stakeholder (state, federal agencies; professional associations, etc.) involvement
46 Number of Prescriptions Issued by Florida Prescribers Dispensed Outside the State of Florida Southeastern States Number of Prescriptions 2009 Alabama 116,000 Louisiana 16,000 North Carolina 48,000 South Carolina 28,000 Other States Arizona 14,000 Vermont 1,700 TOTAL: 223,700 Communication from PMP Center of Excellence dated March 25, 2011.
47 Questions How often does a pharmacy need to upload or report dispensing information to the PDMP? a. 10 days b. 15 days c. 7 days
48 Questions True or False A pharmacist, dispensing a controlled substance in schedules II through IV to a patient or resident at a nursing home, is not required to report to the PDMP.
49 True or False Questions I am not required to view my patient s specific controlled substance history prior to dispensing a controlled substance.
50 True or False Questions The Patient Advisory Report (PAR) is provided for informational purposes only and impose no obligations of any nature or any legal duty on a prescriber, dispenser, pharmacy, or patient.
51 Question What is the penalty for a health care practitioner that does not report their schedule II-IV controlled substance dispensing data? a. Felony b. Misdemeanor
52 Question What is the penalty for disclosure of confidential information in the E-FORCSE database? a. Felony b. Misdemeanor
53 Need Help? Technical Support & Assistance: Health Information Designs, Inc. Phone: Website: hidinc.com/flpdmp 8:00 am 5:00 pm EST
54 Need Help? (cont.) Administrative Assistance: EFORCSE Program Staff Phone: Website: Rebecca Poston, Program Manager Erika Marshall, Program Operations Administrator
Implementation of Florida s PDMP Rebecca R. Poston Program Manager December 1, 2012 Disclosure I have no vested interest in or affiliation with any corporate organizations offering financial support or
Florida s Prescription Drug Monitoring Program http://www.e-forcse.com FACT SHEET FOR HEALTH CARE PRACTITIONERS The Florida Prescription Drug Monitoring Program (PDMP), known as E-FORCSE (Electronic- Florida
2010-2011 Prescription Drug Monitoring Program Annual Report Prescription Drug Monitoring Program E-FORCSE 4052 Bald Cypress Way, Bin C-16 Tallahassee, FL 32399 (850) 245-4444 X 3700 December 1, 2011 Prescription
Prescription Drug Abuse Florida s Health Crisis Overview Florida has been the epicenter for the diversion and abuse of prescription drugs. Prescription drugs killed almost 7 Floridians per day after an
HOUSE OF REPRESENTATIVES STAFF ANALYSIS BILL #: HB 1381 Prescription Drug Monitoring Program SPONSOR(S): Davis TIED BILLS: IDEN./SIM. BILLS: REFERENCE ACTION ANALYST STAFF DIRECTOR or BUDGET/POLICY CHIEF
Training Guide for Florida Practitioners and Pharmacists Florida Department of Health Prescription Drug Monitoring Program March 2014 Note This document is periodically updated. Please refer to the Florida
PDMP name: Agency Responsible: Agency Type: PDMP Website: PDMP Email: Florida Department of Health Department of Health Florida http://www.floridahealth.gov/statistics-and-data/e-forcse/index.html email@example.com
Achieving Better Care by Monitoring All Prescriptions (ABC-MAP) Act 191 of 2014 Board Meeting April 8, 2015 ABC-MAP Board Meeting Agenda Prescription Drug Monitoring Background ABC-MAP Overview Board Responsibilities
This document provides answers to some common questions regarding the reporting of controlled substances to the New Hampshire (PDMP) database. A list of the questions answered in this document is provided
FREQUENTLY ASKED QUESTIONS for the Revised: February 2014 NEW YORK STATE DEPARTMENT OF HEALTH Bureau of Narcotic Enforcement 1-866-811-7957 www.health.ny.gov/professionals/narcotic Online PMP Q: What is
Alabama Department of Public Health Prescription Drug Monitoring Program October 2014 This document is formatted for duplex printing. This page intentionally left blank. Copyright 2009-2014 Health Information
Colorado Prescription Drug Monitoring Program Department of Regulatory Agencies Division of Professions and Occupations State Board of Pharmacy DORA is dedicated to preserving the integrity of the marketplace
State, District, or Territory Alabama Arizona Arkansas Colorado Connecticut Delaware Georgia Guam Criteria for Mandatory Enrollment or Query of PDMP Before renewing an Alabama Controlled Substances Certificate,
NOTICE REQUIREMENTS FOR PRESCRIPTION MONITORING PROGRAMS This project was supported by Grant No. G1299ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this
Oregon Prescription Drug Monitoring Program Terms & Conditions of Account Use Agreement Statutory Authority: The Oregon Health Authority (OHA) was given authority under ORS 431.962 to establish and maintain
Drug Diversion Provider Presentation Controlled Substance Prescribing and Diversion Angela Wallace, R.Ph. Coastal District Inspector, PMP Law Enforcement Officer DHEC Bureau of Drug Control Presentation
Prescription Drug Monitoring Program A Powerful Tool September 16, 2015 No reportable financial interest. Controlled Substance Utilization Review and Evaluation System >16,000 Prescription Painkiller Overdose
Table of Contents User Request for Access... 3 User Login... 3 Upload a Data File... 4 Add Patient Records Direct Dispenser Users... 5 Pharmacy... 8 Search for Patient Records... 10 Search for Error Records...
Controlled Substances Prescription Monitoring Program Dean Wright, RPh Arizona State Board of Pharmacy Controlled Substances Prescription Monitoring Program Arizona s Forty-eighth Legislature passed H.B.
Training Guide for Delaware Practitioners and Pharmacists Delaware Division of Professional Regulation Prescription Monitoring Program August 2014 v1.7 Contents Contents 1 Document Overview... 1 Purpose
ESSENTIAL ELEMENTS OF AN ELECTRONIC PRESCRIPTION MONITORING PROGRAM There currently is a wide variety of factors that characterize state electronic Prescription Monitoring Programs (PMPs), which originated
PRESCRIPTION MONITORING PROGRAM STATE PROFILES LOUISIANA Research current through July 2014. This project was supported by Grant No. G1399ONDCP03A, awarded by the Office of National Drug Control Policy.
PRESCRIPTION MONITORING PROGRAM (PMP) DATA REPORTING MANUAL Effective Date: April 1, 2012 Contact Information: (505) 222-9830 firstname.lastname@example.org 1 P a g e Table of Contents Reporting requirements
Pill Mills, Non-Therapeutic Drug Use, and Prescription Drug Monitoring What to Look for During Investigations ffrey J. Mesaros, PharmD, JD ice Chair Florida Board of Pharmacy ay 21, 2013 Learning Objectives
Bureau of Justice Assistance Harold Rogers Prescription Drug Monitoring Program National Meeting 9/23/2014 Jeanne Tuttle, R.Ph. National Pharmacist Program Managers Pharmacy Benefits Management Services
RHODE ISLAND PRESCRIPTION MONITORING PROGRAM DATA COLLECTION MANUAL Effective Date: October 13, 2014 Optimum Technology, Inc. Contact Information Phone: 866-683-2476 Fax: 866-282-7076 RIRxReport@otech.com
NEW YORK STATE DEPARTMENT OF HEALTH OFFICIAL NEW YORK STATE PRESCRIPTION PROGRAM ELECTRONIC DATA TRANSMISSION Manual of Instructions New York State Department of Health Bureau of Narcotic Enforcement 433
DC DEPARTMENT OF HEALTH Pharmaceutical Warehouse DC Health Care Safety Net ALLIANCE PROGRAM OPERATIONAL PROTOCOLS Operational protocols for the DC Health Care Alliance program through the DOH Pharmaceutical
H.B. 1 H.B. 751 Provisions of the H.B. 1 Appropriations Act The base appropriation for TSBP for FY2016-2017 is approximately $234,000 more than the base appropriation the previous biennium. The majority
PDMP name: Agency Responsible: Agency Type: PDMP Website: PDMP Email: Baumgartner, Chris - Director P O Box 47852 Olympia WA 98504-7852 Office: (360) 236-4806 Fax: (360) 236-2901 Email: Washington Washington
Oregon Health Authority Prescription Drug Monitoring Program December 2015 Contents Contents 1 Document Overview... 1 Purpose and Contents... 1 RxSentry Update... 1 2 System Overview... 3 About the RxSentry
PMP AWAR X E User Support Manual V 1.2 04/09/2014 1 Contents 1 What Is a Requestor?... 3 2 Registration... 3 2.1 Registration Process... 3 2.2 Registering as a Delegate... 7 2.3 Email Verification... 11
North Carolina Department of Health and Human Services Controlled Substance Reporting System August 2014 Contents Contents 1 Document Overview... 1 Purpose and Contents... 1 2 System Overview... 2 About
PDMP name: Agency Responsible: Agency Type: PDMP Website: PDMP Email: Arizona State Board of Pharmacy Pharmacy Board Wright, Dean - Program Director P O Box 18520 Phoenix AZ 85005 Office: (602) 771-2744
Dispenser s Implementation Guide Version 1.11 Florida Department of Health Prescription Drug Monitoring Program eptember 2012 This project was supported by Grant No. 2009-PM-BX-4004 awarded by the Bureau
2015 ANNUAL REVIEW OF PRESCRIPTION MONITORING PROGRAMS Research current through September 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy.
LEGISLATURE OF THE STATE OF IDAHO Sixty-third Legislature Second Regular Session - IN THE SENATE SENATE BILL NO. BY HEALTH AND WELFARE COMMITTEE 0 0 AN ACT RELATING TO EPINEPHRINE AUTO-INJECTORS; AMENDING
FLORIDA'S PROHIBITION ON ADVANCED REGISTERED NURSE PRACTITIONERS (ARNPs) PRESCRIBING CONTROLLED SUBSTANCES AND THE REQUIREMENTS TO REPORT SUCH ACTIVITY Florida is one of the two states that does not allow
Pharmacy Operations Assisting the Pharmacist Pharmacy Technician Training Systems Passassured, LLC Pharmacy Operations, Assisting the Pharmacist PassAssured's Pharmacy Technician Training Program Pharmacy
: Washington CRNAs This FAQ (Frequently Asked Questions) is maintained by. If you have comments or a question that is not answered here, please send it to email@example.com. DISCLAIMER: Please remember,
ARKANSAS PRODUCTS: Any product containing ephedrine, pseudoephedrine, or phenylpropanolamine or any of their salts, isomers, or salts of isomers, alone or in a mixture. (A.C.A. 5-64-212) PRODUCT EXEMPTIONS:
Office of Substance Abuse and Mental Health Services Maine Department of Health and Human Services Prescription Monitoring Program October 2015 Contents Contents 1 System Overview... 1 About RxSentry and
PROPOSED REGULATION OF THE STATE BOARD OF PHARMACY LCB File No. R047-15 September 15, 2015 EXPLANATION Matter in italics is new; matter in brackets [omitted material] is material to be omitted. AUTHORITY:
LOUISIANA PRESCRIPTION MONITORING PROGRAM DATA COLLECTION MANUAL - VERSION 1.0 Revision History Date Version Description Author 12/13/2013 1.0 Initial version Lena Roe (Otech) 1/28/2014 1.1 Updates Lena
RULE The Administration of Medication in Louisiana Public Schools Developed in 1994 by The Louisiana State Board of Elementary and Secondary Education and The Louisiana State Board of Nursing Amendments
Session 3 THIS INITIATIVE IS BEING SUPPORTED BY A SPONSORSHIP FROM PFIZER Disclosure The Immunization Action Coalition has been responsible for all aspects of content development for the enclosed presentation
DIVISION OF MEDICAL QUALITY ASSURANCE BOARD OF PHARMACY 4052 BALD CYPRESS WAY, BIN #C-04 TALLAHASSEE, FLORIDA 32399-3254 (850) 245-4292 COMMUNITY PHARMACY PERMIT APPLICATION AND INFORMATION August 2012
Michael D. Bullek BSP Rph. Commissioner, New Hampshire Board of Pharmacy Legislative changes PDMP program changes 503B outsourcing facilities Rules changes Ph800 review Ph300 Ph400 Ph700 Current issues
South Dakota Prescription Drug Monitoring Program (SD PDMP) SD Academy of Physician Assistants Summer/Fall CME Conference September 6, 2012 Ron Huether, RPh, SD PDMP Kari Shanard Koenders, RPh, PDMP Director
NOTICES OF PROPOSED RULEMAKING Unless exempted by A.R.S. 41-1005, each agency shall begin the rulemaking process by first submitting to the Secretary of State s Office a Notice of Rulemaking Docket Opening
American Indian Health Commission for Washington State October 1, 2015 States with more opioid pain reliever sales tend to have more drug overdose deaths Death rate, 2011, National Vital Statistics System.
0 Page of S. Introduced by Senator Sears Referred to Committee on Date: Subject: Health; prescription drugs; Vermont Prescription Monitoring System Statement of purpose of bill as introduced: This bill
I-STOP: What You Need to Know Lyuba Konopasek, MD Designated Institutional Official NewYork-Presbyterian Hospital August 26, 2013 What is I-STOP? Objectives Why is I-STOP necessary and how is it relevant
Introduction GUIDE TO VERMONT S PHARMACEUTICAL MARKETING DISCLOSURE LAW FOR FY09 DISCLOSURES Published by the Vermont Office of the Attorney General 10/09/09 Effective July 1, 2009, Vermont law bans certain
Massachusetts Substance Abuse Policy and Practices Senator Jennifer L. Flanagan Massachusetts Worcester and Middlesex District November 2014 Substance Abuse and Addiction National and State opioid abuse
State of South Dakota Board of Pharmacy Prescription Drug Monitoring Program User Support Manual Contents 1 What Is a Requestor?... 3 2 Registration... 4 2.1 Registration Process... 4 2.2 Registering as
Pain Management Regulations Affect More Than Pain Management Specialists January 2012 LINDA A. KEEN MSN, JD, LHCRM LAW OFFICE OF LINDA A. KEEN P.A. TALLAHASSEE, FL Of counsel to Pain Management Regulations
Chapter 17. Institutional Pharmacy Louisiana Administrative Code Title 46 Professional and Occupational Standards Subchapter A. General Requirements Part LIII: Pharmacists 1701. Cross References A. For
FREQUENTLY ASKED QUESTIONS FOR ELECTRONIC PRESCRIBING OF CONTROLLED SUBSTANCES EPCS Revised: April 2015 NEW YORK STATE DEPARTMENT OF HEALTH Bureau of Narcotic Enforcement 1-866-811-7957 www.health.ny.gov/professionals/narcotic
Kentucky Board of Medical Licensure 310 Whittington Parkway, Suite 1B Louisville, KY 40222 (502) 429-7150 M E M O R A N D U M TO: FROM: RE: Applicants for Surgical Assistant Certification Dawn Beahl, Surgical
FREQUENTLY ASKED QUESTIONS FOR ELECTRONIC PRESCRIBING OF CONTROLLED SUBSTANCES EPCS Revised: January 2016 NEW YORK STATE DEPARTMENT OF HEALTH Bureau of Narcotic Enforcement 1-866-811-7957 www.health.ny.gov/professionals/narcotic
TABLE OF CONTENTS CHAPTER 8 PRESCRIPTION DRUG MONITORING PROGRAM Section 1. Authority 8-1 Section 2. Transmission of Information Regarding Dispensing of Controlled Substances to Certain Persons 8-1 Section
Prescription Drug Monitoring Programs Montana State Fund 13 th Annual Medical Conference November 1, 2013 Peter Kreiner, Ph.D. PDMP Center of Excellence at Brandeis University Primary non-heroin opiates/synthetics
The House Committee on Health and Human Services offers the following substitute to HB 972: A BILL TO BE ENTITLED AN ACT 1 2 3 4 5 6 7 8 9 10 11 12 13 To amend Chapter 34 of Title 43 of the Official Code
Second Annual Florida 2008 Electronic Prescribing Report FLORIDA CENTER FOR HEALTH INFORMATION AND POLICY ANALYSIS AGENCY FOR HEALTH CARE ADMINISTRATION JANUARY 2009 Better Health Care for All Floridians
STATUTE 32-2501 et seq Arizona Revised Statutes DATE Enacted 1977 REGULATORY BODY Arizona Regulatory Board of Physician Assistants PA DEFINED Person licensed by the board who performs health care tasks
Technical Assistance Guide PDMP Suggested Practices to Ensure Pharmacy Compliance and Improve Data Integrity This project was supported by Grant No. 2011-PM-BX-K001 awarded by the Bureau of Justice Assistance.
Summit Workers Compensation Managed Care Program KENTUCKY How to obtain medical care for a work-related injury or illness. Welcome Summit s workers compensation managed-care organization (Summit MCO) is
1 Maryland Prescription Drug Monitoring Program (PDMP) Hospice Inpatient Waiver Application Background Health-General Article, Section 21-2A-03(f), Annotated Code of Maryland, allows pharmacies to be granted
Commonwealth of Massachusetts Department of Public Health, Office of Prescription Monitoring and Drug Control 99 Chauncy Street, Boston, MA 02111 Tel: 617-753-7310 Email: firstname.lastname@example.org MA ONLINE